Kenji Takanashi

CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates

Kenji Takanashi, Hitoshi Tainaka, Kaoru Kobayashi et al. · Pharmacogenetics · 2000 · 261 citations

Leu359 Variant, Biochemistry, Medicine +13

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

Tatsushi Kodama, Masami Hasegawa, Kenji Takanashi et al. · Cancer Chemotherapy and Pharmacology · 2014 · 241 citations

Neuro-oncology, Oncology, Antitumor Activity +6

Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)

Kazutomo Kinoshita, Kohsuke Asoh, Noriyuki Furuichi et al. · Bioorganic & Medicinal Chemistry · 2011 · 163 citations · Full text

Chemoprevention Strategy, Medicine, Anti-cancer Agent +3

9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5<i>H</i>-benzo[<i>b</i>]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors

Kazutomo Kinoshita, Takamitsu Kobayashi, Kohsuke Asoh et al. · Journal of Medicinal Chemistry · 2011 · 83 citations · Full text

Compound 13D, Molecular Pharmacology, Medicinal Chemistry +12

Prediction of Drug-Drug Interactions based on Time-Dependent Inhibition from High Throughput Screening of Cytochrome P450 3A4 Inhibition

Nobuo Sekiguchi, Atsuko Higashida, Motohiro Kato et al. · Drug Metabolism and Pharmacokinetics · 2009 · 42 citations